B8FK Biofrontera AG

3.082USD2.810 EUR · XETRA-3.44%Mkt Cap: 18.73M USDP/E: —

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States…

Key Statistics

Company
Market Cap18.73M USD
Enterprise Value12.72M USD
Revenue (TTM)17.51M USD
Gross Profit11.96M USD
Net Income (TTM)-4.35M USD
Revenue/Share2.87 USD
Last Price3.082 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees54
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINDE000A4BGGM7
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA5.55
EV/Revenue0.73
P/S1.07
P/B0.84
EPS (TTM)-0.31 USD
EPS (Forward)—
52W Range
2.43540% of range4.058
52W High4.058 USD
52W Low2.435 USD
Profitability
Gross Margin82.71%
Oper. Margin11.29%
EBITDA Margin13.10%
Profit Margin-30.06%
ROE-26.60%
ROA-19.21%
ROIC-9.03%
ROCE-6.87%
Growth
Revenue Growth78.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.83M USD
CapEx (TTM)55.94K USD
FCF Margin—
FCF Yield—
Net Debt-6.01M USD
Net Debt/EBITDA-2.62
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio3.60
Quick Ratio2.74
Book Value/Sh3.68 USD
Cash/Share1.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:21
Split DateMay 14, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.08M
Float1.40M
Insiders77.00%
Institutions0.00%
Technical
SMA 503.316 (-7.0%)
SMA 2002.884 (+6.9%)
Beta-0.51
S&P 52W Chg12.00%
Avg Vol (30d)316
Avg Vol (10d)169
Technical Indicators
RSI (14)43.4
MACD-0.0200
MACD Signal0.0053
MACD Hist.-0.0253
BB Upper3.443 USD
BB Middle3.256 USD
BB Lower3.070 USD
BB Width11.44%
ATR (14)0.1699 USD
Vol Ratio (20d)0.50x

About Biofrontera (ETR: B8FK)

›

Biofrontera (ETR: B8FK) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 54 employees.

The shares were at 2.810 EUR on 19 November 2026, up 10.2% over 52 weeks. Its 52-week range is 2.220 EUR to 3.700 EUR: the price is 24.1% below the high and 26.6% above the low.

Its market capitalisation is 17.08M EUR.

Biofrontera reports return on equity of -26.6%, an operating margin of 11.3% and revenue up 78.2% year over year.

It holds more cash than debt, a net cash position of 5.48M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.